Joseph Thome
Stock Analyst at TD Cowen
(1.64)
# 3,247
Out of 5,150 analysts
21
Total ratings
44.44%
Success rate
-2.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $525 → $575 | $490.21 | +17.30% | 3 | Feb 26, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $115 → $117 | $93.04 | +25.75% | 2 | Feb 26, 2026 | |
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $64.29 | -2.01% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $6.65 | +50.38% | 1 | Oct 31, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $79.31 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $30.39 | - | 1 | Nov 25, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $29.34 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $29.28 | +16.12% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $4.12 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi Therapeutics | Initiates: Outperform | n/a | $1.60 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $43.05 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.69 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $164.08 | -20.77% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.82 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.50 | - | 1 | Nov 23, 2021 |
United Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $525 → $575
Current: $490.21
Upside: +17.30%
Mirum Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $115 → $117
Current: $93.04
Upside: +25.75%
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $64.29
Upside: -2.01%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $6.65
Upside: +50.38%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $79.31
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $30.39
Upside: -
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $29.34
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $29.28
Upside: +16.12%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $4.12
Upside: -
Metagenomi Therapeutics
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.60
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $43.05
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.69
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $164.08
Upside: -20.77%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $13.82
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.50
Upside: -